Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Schizophrenia trials have been too small, short and exclusionary, leaving the most disabled patients under-represented and key outcomes neglected. Future research should match the illness burden through sustained funding, representative recruitment, multidomain assessment, and adaptive, platform and SMART designs that test treatments efficiently and produce evidence relevant to patients' lives.

More information Original publication

DOI

10.1192/bjp.2026.10657

Type

Journal article

Publication Date

2026-05-15T00:00:00+00:00

Pages

1 - 4

Total pages

3

Keywords

Schizophrenia, negative symptoms, platform studies, treatment-resistant, trial design